11.19
+0.49(+4.58%)
Currency In USD
| Previous Close | 10.7 |
| Open | 10.65 |
| Day High | 11.38 |
| Day Low | 10.54 |
| 52-Week High | 12.34 |
| 52-Week Low | 2.24 |
| Volume | 699,099 |
| Average Volume | 833,287 |
| Market Cap | 522.6M |
| PE | -2.98 |
| EPS | -3.75 |
| Moving Average 50 Days | 10.22 |
| Moving Average 200 Days | 5.94 |
| Change | 0.49 |
If you invested $1000 in 4D Molecular Therapeutics, Inc. (FDMT) since IPO date, it would be worth $276.3 as of December 05, 2025 at a share price of $11.19. Whereas If you bought $1000 worth of 4D Molecular Therapeutics, Inc. (FDMT) shares 3 years ago, it would be worth $482.95 as of December 05, 2025 at a share price of $11.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
4DMT to Participate in 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 20, 2025 1:00 PM GMT
EMERYVILLE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatmen
4DMT Appoints Kristian Humer as Chief Financial Officer
GlobeNewswire Inc.
Nov 17, 2025 11:00 AM GMT
EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatmen
4DMT to Participate in Jefferies 2025 London Healthcare Conference
GlobeNewswire Inc.
Nov 06, 2025 9:05 PM GMT
EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatmen